Glycated albumin may be a choice, but not an alternative marker of glycated hemoglobin for glycemic control assessment in diabetic patients undergoing maintenance hemodialysis

Chinese Medical Journal

Volumn 126, Issue 17, 2013, Pages 3295-3300

  Chen, Feng Kun ^a   Sun, Xue Feng ^a   Zhang, Dong ^a   Cui, Shao Yuan ^a   Chen, Xiang Mei ^a   Wei, Ri Bao ^a   Lu, Ju Ming ^a   Li, Ji Jun ^a   Liu, Wen Hu ^b   Zhang, Dong Liang ^b   Zhang, Zhi Min ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c 309TH HOSPITAL OF PLA   (China)

Author keywords

Diabetes mellitus; Glycated albumin; Glycated hemoglobin; Maintenance hemodialysis

Indexed keywords

ALBUMIN; ERYTHROPOIETIN; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84883504988     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130162     Document Type: Article

References (23)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
4. Tsujimoto Y, Ishimura E, Tahara H, Kakiya R, Koyama H, Emoto M, et al. Poor glycemic control is a significant predictor of cardiovascular events in chronic hemodialysis patients with diabetes. Ther Apher Dial 2009; 13: 358-365.
5. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998 9: S16-S23.
6. US Renal Data System: USRDS 2009 annual data report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2009, 1st Edition: 489.
7. Ichikawa H, Nagake Y, Takahashi M, Nakazono H, Kawabata K, Shikata K, et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? Nippon Jinzo Gakkai Shi 1996; 38: 305-308.
8. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830.
9. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307.
10. Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes JW. Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci U S A 1979; 76: 4258-4261.
11. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062-1068.
12. Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007; 46: 807-814.
13. Fukuoka K, Nakao K, Morimoto H, Nakao A, Takatori Y, Arimoto K, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008; 13: 278-283.
14. Diabetes Section of Chinese Medical Association. Chinese prophylaxis and treatment guideline of type 2 diabetes mellitus (2007). Chin Med J 2008; 88: 1227-1245.
15. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61: 377-382.
16. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009; 32: 1137-1142.
17. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
18. Chujo K, Shima K, Tada H, Oohashi T, Minakuchi J, Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 2006; 53: 223-228.
19. Koga M, Matsumoto S, Saito H, Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 2006; 53: 387-391.
20. Uzu T, Hatta T, Deji N, Izumiya T, Ueda H, Miyazawa I, et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Ther Apher Dial 2009; 13: 89-94.
21. Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010; 30: 72-79.
22. Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J 2008; 55: 503-507.
23. Nagayama H, Inaba M, Okabe R, Emoto M, Ishimura E, Okazaki S, et al. Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother 2009; 63: 236-240.